Det gælder især for patienter, som tidligere er behandlet med anthracykliner eller som har en underliggende hjerte - eller lungesygdom.
While cardiotoxicity unequivocally related to Abraxane has not been demonstrated, cardiac events are not uncommon in the indicated population, especially in patients who have previously received anthracyclines or have underlying cardiac or pulmonary disease.